Part 2 of our May 18–22, 2026 roundup digs into a first-in-class Bicycle Toxin Conjugate for bladder cancer, a non-surgical DNA immunotherapy clearing HPV-driven cervical pre-cancer, anoff-the-shelf cancer vaccine extending remission in ovarian cancer, an engineered IL-2 antibody pulling responses out of melanoma that had resisted every checkpoint inhibitor, and a topical hair-loss drug that may finally give men a side-effect-light alternative to finasteride.
In Part 2 we cover:6. Bicycle Therapeutics — Zelenectide Pevedotin (BT8009) for Advanced Bladder (Urothelial) Cancer (Phase 2/3)7. ApolloBio (with INOVIO) — VGX-3100 for HPV-16/18 High-Grade Cervical Pre-Cancer (Phase 3)8. OSE Immunotherapeutics — Tedopi for Platinum-Sensitive Recurrent Ovarian Cancer (Phase 2)9. Aulos Bioscience — Imneskibart (AU-007) for Checkpoint-Inhibitor-Refractory Metastatic Melanoma (Phase 2)10. Cosmo Pharmaceuticals — Clascoterone 5% Topical Solution for Male Androgenetic Alopecia (Phase 3)
The Bicycle Therapeutics readout is a fascinating proof-of-concept. Instead of a giant antibody hauling chemo to a tumor, Bicycle uses a tiny constrained peptide as the targeting head — small enough to penetrate solid tumors more deeply and clear from the body faster than a traditional antibody-drugconjugate. Positive Phase 2 data in advanced bladder cancer suggest this 'bicycle' platform could become a new way to deliver targeted chemotherapy across many cancers. We also pull back to identify the big pipeline themes connecting all ten of this week's readouts.
Catch Part 1 if you missed it. Subscribe at TrialBreaks.com
#biomedicine #clinicaltrials #science #oncology #bladdercancer #ovariancancer #melanoma #immunotherapy #HPV #cervicalcancer #dermatology #hairloss #vaccines#drugdiscovery #ADC